$0.36
4.36%
Downside
Day's Volatility :11.49%
Upside
7.46%
4.72%
Downside
52 Weeks Volatility :90.98%
Upside
90.53%
Period | Aptose Biosciences Inc | Index (Russel 2000) |
---|---|---|
3 Months | -60.55% | 0.0% |
6 Months | -78.4% | 0.0% |
1 Year | -90.52% | 0.0% |
3 Years | -99.18% | -22.3% |
Market Capitalization | 7.0M |
Book Value | - $0.12 |
Earnings Per Share (EPS) | -4.24 |
PEG Ratio | 0.0 |
Wall Street Target Price | 14.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -136.29% |
Return On Equity TTM | -694.13% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -40.9M |
Diluted Eps TTM | -4.24 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -4.32 |
EPS Estimate Next Year | -2.19 |
EPS Estimate Current Quarter | -1.18 |
EPS Estimate Next Quarter | -1.19 |
What analysts predicted
Upside of 3927.78%
Sell
Neutral
Buy
Aptose Biosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Aptose Biosciences Inc | -27.27% | -78.4% | -90.52% | -99.18% | -99.01% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Aptose Biosciences Inc | NA | NA | 0.0 | -4.32 | -6.94 | -1.36 | NA | -0.12 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Aptose Biosciences Inc | Buy | $7.0M | -99.01% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Aptose Biosciences Inc
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 127.6%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 168.4%
Armistice Capital, LLC
DRW Securities, LLC
Sigma Planning Corp
Nantahala Capital Management, LLC
Morgan Stanley - Brokerage Accounts
Cetera Advisors LLC
aptose biosciences is a science-driven biotechnology company advancing first-in-class agents to treat life-threatening cancers, such as acute myeloid leukemia (aml), high-risk myelodysplastic syndromes (mds) and other hematologic malignancies. based on insights into the genetic and epigenetic profiles of certain cancers and patient populations, aptose is building a pipeline of novel oncology therapies directed at dysregulated processes and signaling pathways. aptose is developing targeted medicines for precision treatment of these diseases, based on a patient’s specific gene expression signature. in the treatment of cancer, this strategy is intended to optimize efficacy and quality of life by minimizing the cytotoxic side effects associated with conventional therapies. cg026806 (cg’806) is a highly potent first-in-class pan-flt3/btk inhibitor. this small molecule therapeutic agent, exhibits a picomolar ic50 toward the fms-like tyrosine kinase 3 with the internal tandem duplication (flt
Organization | Aptose Biosciences Inc |
Employees | 35 |
CEO | Dr. William G. Rice Ph.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$0.36
-4.1%
Keyarch Acquisition Corp
$0.36
-4.1%
Connexa Sports Technologies Inc
$0.36
-4.1%
Us Value Etf
$0.36
-4.1%
First Wave Biopharma Inc
$0.36
-4.1%
Global X Msci Next Emerging
$0.36
-4.1%
Fat Projects Acquisition Corp
$0.36
-4.1%
Capital Link Global Fintech
$0.36
-4.1%
Applied Uv Inc
$0.36
-4.1%